Home › Companies › C4 Therapeutics, Inc. › 2025-2026
At C4 Therapeutics, Inc.'s shareholder meeting held June 24, 2026, in the 2025-2026 proxy season, 93 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 408 separate fund positions. On the most widely held item on that ballot — TO CAST A NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: C4 Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 24, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and C4 Therapeutics, Inc.’s Form 8-K, filed June 24, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 24, 2026: 6 items on C4 Therapeutics, Inc.’s Form 8-K, filed June 24, 2026: 2 approved · 4 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore C4 Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are C4 Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Andrew J. Hirsch | 47,797,964 | -- | -- | 8,247,406 | 21,049,125 | 85% | Not verified | — |
| Elect Director: Stephen Fawell, Ph.D. | 47,811,414 | -- | -- | 8,233,956 | 21,049,125 | 85% | Not verified | — |
| Elect Director: Utpal Koppikar | 46,491,892 | -- | -- | 9,553,478 | 21,049,125 | 83% | Not verified | — |
| B) The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. | 54,935,574 | 1,070,926 | 38,870 | -- | 21,049,125 | 98% | Not verified | — |
| C) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. | 76,891,210 | 185,427 | 17,858 | -- | 0 | 99.7% | Approved | — |
| D) The Company's stockholders approved an amendment to the Company's 2020 Stock Option and Incentive Plan to amend the evergreen provision to include any outstanding pre-funded warrants in the total number of shares of common stock that are | 33,713,572 | 22,287,787 | 44,011 | -- | 21,049,125 | 60% | Approved | — |
Source: C4 Therapeutics, Inc., Form 8-K, filed with the SEC on June 24, 2026 — read the filing on EDGAR.
Each item below shows how the 93 asset managers that disclosed a C4 Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Andrew Hirsch
C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Andrew J. Hirsch”): 47,797,964 for, 8,247,406 withheld, per its Form 8-K filed June 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 22 asset managers below reported 10,043,365 for, 617,609 withheld, 28,387 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,810,416 | 0 | 20 | 6,331 | For |
| WASATCH FUNDS TRUST | 2,893,310 | 0 | 0 | 0 | For |
| Fidelity | 1,522,507 | 0 | 0 | 0 | For |
| BlackRock | 792,389 | 0 | 0 | 0 | For |
| Jackson National | 471,626 | 0 | 26,646 | 0 | Mixed |
| Charles Schwab | 452,048 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 343,901 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 120,000 | Withhold |
| American Century | 0 | 0 | 0 | 97,172 | Withhold |
| T. Rowe Price | 71,546 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 20,900 | Withhold |
| Equitable | 13,199 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 9,344 | Withhold |
| Goldman Sachs | 8,899 | 0 | 0 | 0 | For |
| SA FUNDS INVESTMENT TRUST | 0 | 0 | 0 | 8,052 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 6,970 | Withhold |
| Northern Trust | 4,313 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 3,972 | Withhold |
| Invesco | 3,112 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 1,721 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 507 | Withhold |
| Guggenheim | 0 | 0 | 0 | 460 | Withhold |
Combines 4 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Stephen Fawell, Ph.D.
C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Stephen Fawell, Ph.D.”): 47,811,414 for, 8,233,956 withheld, per its Form 8-K filed June 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 22 asset managers below reported 10,050,203 for, 610,771 withheld, 28,387 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,816,747 | 0 | 20 | 0 | For |
| WASATCH FUNDS TRUST | 2,893,310 | 0 | 0 | 0 | For |
| Fidelity | 1,522,507 | 0 | 0 | 0 | For |
| BlackRock | 792,389 | 0 | 0 | 0 | For |
| Jackson National | 471,626 | 0 | 26,646 | 0 | Mixed |
| Charles Schwab | 452,048 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 343,901 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 120,000 | Withhold |
| American Century | 0 | 0 | 0 | 97,172 | Withhold |
| T. Rowe Price | 71,546 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 20,900 | Withhold |
| Equitable | 13,199 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 9,344 | Withhold |
| Goldman Sachs | 8,899 | 0 | 0 | 0 | For |
| SA FUNDS INVESTMENT TRUST | 0 | 0 | 0 | 8,052 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 6,970 | Withhold |
| Northern Trust | 4,313 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 3,972 | Withhold |
| Invesco | 3,112 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 1,721 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 507 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 0 | 0 | 460 | Withhold |
Combines 4 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Utpal Koppikar
C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Utpal Koppikar”): 46,491,892 for, 9,553,478 withheld, per its Form 8-K filed June 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 22 asset managers below reported 9,574,994 for, 1,085,977 withheld, 28,390 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,807,305 | 0 | 23 | 9,439 | For |
| WASATCH FUNDS TRUST | 2,893,310 | 0 | 0 | 0 | For |
| Fidelity | 1,522,507 | 0 | 0 | 0 | For |
| BlackRock | 792,389 | 0 | 0 | 0 | For |
| Jackson National | 471,626 | 0 | 26,646 | 0 | Mixed |
| Charles Schwab | 0 | 0 | 0 | 452,048 | Withhold |
| Dimensional | 0 | 0 | 0 | 343,901 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 120,000 | Withhold |
| American Century | 0 | 0 | 0 | 97,172 | Withhold |
| T. Rowe Price | 71,546 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 20,900 | Withhold |
| Equitable | 13,199 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 9,344 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 8,899 | Withhold |
| SA FUNDS INVESTMENT TRUST | 0 | 0 | 0 | 8,052 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 6,970 | Withhold |
| Northern Trust | 0 | 0 | 0 | 4,313 | Withhold |
| ProShares | 0 | 0 | 0 | 3,972 | Withhold |
| Invesco | 3,112 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 1,721 | 0 | Abstain |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 507 | Withhold |
| Guggenheim | 0 | 0 | 0 | 460 | Withhold |
60% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR 2020 STOCK OPTION AND INCENTIVE PLAN TO AMEND THE EVERGREEN PROVISION TO INCLUDE ANY OUTSTANDING PRE-FUNDED WARRANTS IN THE TOTAL NUMBER OF SHARES OF COMMON STOCK THAT ARE ISSUED AND OUTSTANDING AS OF EACH DECEMBER 31.
C4 Therapeutics, Inc.’s own tally for this item (“d) The Company's stockholders approved an amendment to the Company's 2020 Stock Option and Incentive Plan to amend the evergreen provision to include any outstanding pre-funded warrants in the total number of shares of c”): 33,713,572 for, 22,287,787 against — passed, per its Form 8-K filed June 24, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “d) The Company's stockholders approved an amendment to the Company's 2020 Stock Option and Incentive Plan to amend the evergreen provision to include any outstanding pre-funded warrants in the total number of shares of common stock that are issued and outstanding as of each December 31 for purposes…”
Support: 60% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 23 asset managers below reported 3,369,736 for, 7,327,625 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,800 | 3,811,967 | 0 | 0 | Against |
| WASATCH FUNDS TRUST | 2,893,310 | 0 | 0 | 0 | For |
| Fidelity | 0 | 1,522,507 | 0 | 0 | Against |
| BlackRock | 0 | 792,389 | 0 | 0 | Against |
| Jackson National | 471,626 | 26,646 | 0 | 0 | Mixed |
| Charles Schwab | 0 | 452,048 | 0 | 0 | Against |
| Dimensional | 0 | 343,901 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 120,000 | 0 | 0 | Against |
| American Century | 0 | 97,172 | 0 | 0 | Against |
| T. Rowe Price | 0 | 71,546 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 20,900 | 0 | 0 | Against |
| Equitable | 0 | 13,199 | 0 | 0 | Against |
| Victory Capital | 0 | 9,344 | 0 | 0 | Against |
| Goldman Sachs | 0 | 8,899 | 0 | 0 | Against |
| SA FUNDS INVESTMENT TRUST | 0 | 8,052 | 0 | 0 | Against |
| Rangeley Capital, LLC | 0 | 8,000 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 6,970 | 0 | 0 | Against |
| Northern Trust | 0 | 4,313 | 0 | 0 | Against |
| ProShares | 0 | 3,972 | 0 | 0 | Against |
| Invesco | 0 | 3,112 | 0 | 0 | Against |
| John Hancock | 0 | 1,721 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 507 | 0 | 0 | Against |
| Guggenheim | 0 | 460 | 0 | 0 | Against |
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: TO CAST A NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
C4 Therapeutics, Inc.’s own tally for this item (“b) The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.”): 54,935,574 for, 1,070,926 against, per its Form 8-K filed June 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,816,764 | 2 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,893,310 | 0 | 0 | 0 | For |
| Fidelity | 1,522,507 | 0 | 0 | 0 | For |
| BlackRock | 792,389 | 0 | 0 | 0 | For |
| Jackson National | 498,272 | 0 | 0 | 0 | For |
| Charles Schwab | 452,048 | 0 | 0 | 0 | For |
| Dimensional | 343,901 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 120,000 | 0 | 0 | Against |
| American Century | 0 | 97,172 | 0 | 0 | Against |
| T. Rowe Price | 71,546 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 20,900 | 0 | 0 | 0 | For |
| Equitable | 13,199 | 0 | 0 | 0 | For |
| Victory Capital | 9,344 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 8,899 | 0 | 0 | Against |
| SA FUNDS INVESTMENT TRUST | 8,052 | 0 | 0 | 0 | For |
| Prudential/PGIM | 6,970 | 0 | 0 | 0 | For |
| Northern Trust | 4,313 | 0 | 0 | 0 | For |
| ProShares | 3,972 | 0 | 0 | 0 | For |
| Invesco | 3,112 | 0 | 0 | 0 | For |
| John Hancock | 1,721 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 507 | 0 | 0 | 0 | For |
| Guggenheim | 460 | 0 | 0 | 0 | For |
Fund voting reports, all 22 managers: 10,463,287 for, 226,073 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 8,000,000 | 0 | 0 | 0 | For |
| Lynx1 Capital Management LP | 5,993,801 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 3,803,942 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 3,210,681 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 3,131,910 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 2,955,304 | 0 | 0 | 0 | For |
| Citadel | 2,384,953 | 0 | 0 | 0 | For |
| Two Sigma | 1,836,266 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 1,754,824 | 31,379 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,268,710 | 0 | 0 | 0 | For |
| BlackRock | 1,192,954 | 93 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,030,285 | 0 | 0 | 0 | For |
| Renaissance | 794,599 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 706,817 | 0 | 0 | 0 | For |
| Fidelity | 692,810 | 0 | 0 | 0 | For |
| CONGRESS ASSET MANAGEMENT CO | 628,271 | 63,138 | 0 | 0 | Mixed |
| Vanguard | 529,466 | 0 | 0 | 0 | For |
| Charles Schwab | 452,172 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 300,000 | 0 | 0 | 0 | For |
| DE Shaw | 287,286 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 242,470 | 0 | 0 | 0 | For |
| Man Group plc | 201,287 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 178,646 | 0 | 0 | 0 | For |
| WELLS FARGO CLEARING SERVICES, LLC | 178,059 | 0 | 0 | 0 | For |
| Dimensional | 146,326 | 0 | 0 | 0 | For |
Institutional-manager reports, all 81 managers: 43,244,117 for, 347,354 against, 81 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.7% Approved · of votes cast
Description as filed by funds: TO RATIFY THE ENGAGEMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.
C4 Therapeutics, Inc.’s own tally for this item (“c) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 76,891,210 for, 185,427 against — passed, per its Form 8-K filed June 24, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “c) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 22 asset managers below reported 10,689,361 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,816,767 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,893,310 | 0 | 0 | 0 | For |
| Fidelity | 1,522,507 | 0 | 0 | 0 | For |
| BlackRock | 792,389 | 0 | 0 | 0 | For |
| Jackson National | 498,272 | 0 | 0 | 0 | For |
| Charles Schwab | 452,048 | 0 | 0 | 0 | For |
| Dimensional | 343,901 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 120,000 | 0 | 0 | 0 | For |
| American Century | 97,172 | 0 | 0 | 0 | For |
| T. Rowe Price | 71,546 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 20,900 | 0 | 0 | 0 | For |
| Equitable | 13,199 | 0 | 0 | 0 | For |
| Victory Capital | 9,344 | 0 | 0 | 0 | For |
| Goldman Sachs | 8,899 | 0 | 0 | 0 | For |
| SA FUNDS INVESTMENT TRUST | 8,052 | 0 | 0 | 0 | For |
| Prudential/PGIM | 6,970 | 0 | 0 | 0 | For |
| Northern Trust | 4,313 | 0 | 0 | 0 | For |
| ProShares | 3,972 | 0 | 0 | 0 | For |
| Invesco | 3,112 | 0 | 0 | 0 | For |
| John Hancock | 1,721 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 507 | 0 | 0 | 0 | For |
| Guggenheim | 460 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 110,567,222 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.45% |
| 2 | WASATCH FUNDS TRUST | 2.62% |
| 3 | Fidelity | 1.38% |
| 4 | BlackRock | 0.72% |
| 5 | Jackson National | 0.45% |
| 6 | Charles Schwab | 0.41% |
| 7 | Dimensional | 0.31% |
| 8 | BRIDGEWAY FUNDS INC | 0.11% |
| 9 | American Century | 0.09% |
| 10 | T. Rowe Price | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 7.24% |
| 2 | Lynx1 Capital Management LP | 5.42% |
| 3 | Soleus Capital Management, L.P. | 3.44% |
| 4 | ORBIMED ADVISORS LLC | 2.90% |
| 5 | Bain Capital Life Sciences Investors, LLC | 2.83% |
| 6 | WASATCH ADVISORS LP | 2.67% |
| 7 | Citadel | 2.16% |
| 8 | Two Sigma | 1.66% |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 1.62% |
| 10 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.15% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Sirenia Capital Management LP | — | 13G |
| Lynx1 Capital Management LP | — | 13G |
| Entities Affiliated with OrbiMed Advisors | — | DEF14A |
| RA Capital Management, L.P. | — | 13G |
| Soleus Capital Management, L.P. | — | DEF14A |
| Lynx1 Capital Advisors LLC | — | DEF14A |
| Soleus Capital Master Fund, L.P. | — | 13G |
| Morgan Stanley | — | 13F |
| Squadron Master Fund LP | — | 13G |
| Bain Capital Life Sciences Investors, LLC | — | DEF14A |
Percentages above are of 110,567,222 shares outstanding, as reported by C4 Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from C4 Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
C4 Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “C4 Therapeutics (CCCC) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/c4-therapeutics-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.